
Study or Subgroup	Events	Total	Weight (common)	_	Proportion [95% CI]	Serious Arrhythmias QTc Adverse Drug Reactions
drug = Osimertinib						i
Teranishi,2022	1	61	0.2%	0.3%	0.02 [0.00; 0.09]	i -
Lorenzi,2022	1	126	0.6%	1.1%	0.01 [0.00; 0.04]	↓
Kishikawa,2020	1	56	0.1%			<u> </u>
Kunimasa,2020	2	123	0.4%		0.02 [0.00; 0.06]	}-
NCT02474355,2019	19	3014				<u>.</u>
NCT02094261,2015	2	210				
Malik,2022 Nakao,2019	1 1	60 36	0.1% 0.1%			
Watanabe,2024	4	583			0.03 [0.00; 0.13]	
Singh,2023	2	82				! !
Chen,2024	1	17	0.0%			-
2014-000531-17,2024	4	210	0.6%			+ -
Eide,2020	1	199	1.6%		• '	+
Total (common effect, 95% Cl)	4777	36.4%		0.01 [0.00; 0.01])
Total (random effect, 95% CI)		(5		36.0%	0.01 [0.00; 0.01]	
Heterogeneity: $Tau^2 = 0$; $Chi^2 = 6.3$	33, df = 12	(P = 0.8)	3988); I ⁻ = 0%)		! !
drug = Afatinib	_			.	0.0010.00	: ! !
Tu,2022	2	541	6.8%			
NCT02131259,2016	4	1602				<u>•</u>
2009-014563-39,2013 NCT02044380 2016	6	1154				1
NCT02044380,2016 Total (common effect, 95% Cl)	1	14 3311	0.0% 52.0%	0.0%	0.07 [0.00; 0.34] 0.00 [0.00; 0.01]	<u> </u>
Total (random effect, 95% CI)	,	JJII	JZ.U%	45.8%	0.00 [0.00; 0.01]	
Heterogeneity: $Tau^2 = 0$; $Chi^2 = 2.2$	22, df = 3 (F	P = 0.52	276); $I^2 = 0\%$	1 J.U /0	0.00 [0.00, 0.01]	
drug = Erlotinib						
Markóczy,2018	2	62	0.1%	0.2%	0.03 [0.00; 0.11]	! ! •
Brueckl,2018	1	385				in the state of th
Total (common effect, 95% CI)		447	5.9%		0.00 [0.00; 0.01]	1
Total (random effect, 95% CI)	,		-	8.3%		•
Heterogeneity: Tau ² = 0.0002; Chi ²	2 = 1.72, df	= 1 (P	= 0.1892); I ² :		L	
drug = Befotertinib						
Lu,2022 (50mg)	2	176	0.7%	1.3%	0.01 [0.00; 0.04]	
Jian,2022 (25mg)	1	1	0.0%	0.0%	1.00 [0.03; 1.00]	<u> </u>
Total (common effect, 95% Cl))	177	0.7%		0.01 [0.00; 0.03]	•
Total (random effect, 95% CI)				1.3%	0.46 [0.00; 1.00]	
Heterogeneity: Tau ² = 0.4418; Chi ²	$^2 = 10.42$, c	df = 1 (F	$P = 0.0012$); I^2	² = 90.4%		
drug = Gefitinib						
Maimaitituersun,2023	3	122	0.3%	0.5%	0.02 [0.01; 0.07]	
drug = Rezivertinib						
Shi,2022	4	226	0.7%	1.2%	0.02 [0.00; 0.04]	i
drug = Oritinib						i
Xiong,2022	3	286	1.4%	2.3%	0.01 [0.00; 0.03]	•
drug = Nazartinib						
Tan,2020 (150mg)	3	118	0.2%	0.4%	0.03 [0.01; 0.07]	
Tan,2020 (225mg)	1	28	0.0%			
Total (common effect, 95% CI))	146	0.3%		0.03 [0.00; 0.05]	♦
Total (random effect, 95% CI) Heterogeneity: $Tau^2 = 0$; $Chi^2 = 0.0$)7 df = 1 /1	D _	862) · I ² – 0°/	0.5%	0.03 [0.00; 0.05]	♦
	,, ui = 1 (f	- 0.78	υω∠ <i>j</i> , ι = U%			
drug = Abivertinib	4	00	0.004	0.007	0.05.10.00.00.51	
Zhou,2022 (150mg)	1	20		0.0%	0.05 [0.00; 0.25]	['
Zhou,2022 (300mg)	. 4	272 292	1.0%	1.7%	0.01 [0.00; 0.04]	
Total (common effect, 95% Cl) Total (random effect, 95% Cl)	,	494	1.0%	1. 7 %	0.02 [0.00; 0.03] 0.02 [0.00; 0.03]	
Heterogeneity: $Tau^2 = 0$; $Chi^2 = 0.5$	51, df = 1 (F	P = 0.47	738); $I^2 = 0\%$	1.1 70	0.02 [0.00, 0.03]	N ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !
drug = Almonertinib						! ! !
Yang,2020 (110mg)	2	244	1.4%	2.4%	0.01 [0.00; 0.03]	-
drug = Sunvozertinib						! !
Wang,2022	1	20	0.0%	0.0%	0.05 [0.00; 0.25]	! !
Total (common effect, 95% CI))	10048	100.0%		0.01 [0.00; 0.01]	
Total (random effect, 95% CI)	,		. 5515 /0	100.0%	0.01 [0.00; 0.01]	
Heterogeneity: Tau ² < 0.0001; Chi ²	2 = 34.67, c	df = 29 (P = 0.2155):	_	. [2:23, 2:4.]	
Test for subgroup differences (com					48)	0 0.2 0.4 0.6 0.8 1
Test for subgroup differences (rand		,	•	,	•	

Study or Subgroup	Events	Total	Weight (common)	_	Proportion [95% CI	Serious Heart Failure Adverse Drug Reactions
drug = Osimertinib						
Lorenzi,2022	1	126	0.8%	0.9%	0.01 [0.00; 0.04]	-
Kunimasa,2020	4	123	0.2%	0.2%	0.03 [0.01; 0.08]	
Fujiwara,2023	1	8	0.0%	0.0%	0.12 [0.00; 0.53]	+
Park,2020	1	40	0.1%	0.1%	0.03 [0.00; 0.13]	
NCT02474355,2019	15	3014	29.5%	28.5%	0.00 [0.00; 0.01]	•
Kiura,2018	1	301	4.4%	4.8%	0.00 [0.00; 0.02]	•
Provencio,2021	1	155	1.2%	1.3%	0.01 [0.00; 0.04]	
Nakao,2019	1	36	0.1%	0.1%	0.03 [0.00; 0.15]	+
Ang,2023	1	110	0.6%	0.7%	0.01 [0.00; 0.05]	
Park,2024	1	73	0.3%	0.3%	0.01 [0.00; 0.07]	
Total (common effect, 95% CI)		3986	37.1%		0.01 [0.00; 0.01]	İ
Total (random effect, 95% CI)				36.8%	0.01 [0.00; 0.01]	
Heterogeneity: $Tau^2 = 0$; $Chi^2 = 6.3$	7, df = 9 (I	P = 0.7	$(022); I^2 = 0\%$		• , •	
drug = Afatinib						
Tu,2022	1	541	14.2%	14.8%	0.00 [0.00; 0.01]	Ė
NCT02131259,2016	4		31.2%	29.9%	0.00 [0.00; 0.01]	+
NCT02047903,2018	1	152	1.1%	1.3%	0.01 [0.00; 0.04]	-
2009–014563–39,2013	5	1154	13.0%		• '	•
Nakamura,2020	1	30	0.0%			-
Total (common effect, 95% CI)	•	3479	59.6%		0.00 [0.00; 0.00]	
Total (random effect, 95% CI)		0470	00.070	59.5%		
Heterogeneity: $Tau^2 = 0$; $Chi^2 = 2.1$	5, df = 4 (I	P = 0.7	$(080); I^2 = 0\%$		0.00 [0.00, 0.00]	
drug = Gefitinib						; ; ;
Douillard,2014	2	107	0.3%	0.3%	0.02 [0.00; 0.07]	<u> </u>
Cappuzzo,2016	1	58	0.2%	0.2%	0.02 [0.00; 0.09]	! !
Total (common effect, 95% CI)		165	0.4%		0.02 [0.00; 0.04]	•
Total (random effect, 95% CI)			-	0.5%		
Heterogeneity: $Tau^2 = 0$; $Chi^2 = 0$, $Chi^2 = 0$	df = 1 (P =	0.9463	3); $I^2 = 0\%$	01070	0.02 [0.00, 0.0.]	
drug = Rezivertinib						
Shi,2022	4	226	0.6%	0.7%	0.02 [0.00; 0.04]	<u> </u>
					. , .	
drug = Nazartinib	4	4.5	0.40/	0.40/	0.00.00.00.0.401	
Tan,2020 (150mg)	1	45	0.1%			
Tan,2020 (225mg)	1	28	0.0%		• '	
Total (common effect, 95% CI)		73	0.1%		0.03 [0.00; 0.06]	
Total (random effect, 95% CI)			•	0.2%	0.03 [0.00; 0.06]	
Heterogeneity: $Tau^2 = 0$; $Chi^2 = 0.1$	1, df = 1 (l	P = 0.7	$(444); I^2 = 0\%$)		
drug = Erlotinib						
Park,2015	1	207	2.1%	2.3%	0.00 [0.00; 0.03]	i
drug = Mobocertinib	,					
Hida,2021 (160mg)	1	33	0.1%	0.1%	0.03 [0.00; 0.16]	!
Total (common effect, 95% CI)		8169	100.0%		0.00 [0.00; 0.01]	
Total (random effect, 95% Cl)				100.0%	0.00 [0.00; 0.01]	!
Heterogeneity: Tau ² < 0.0001; Chi ²		_	` '			
Test for subgroup differences (com-						0 0.1 0.2 0.3 0.4 0.5
Test for subgroup differences (rand	om effects	s): Chi ²	= 9.34, df $= 0$	6 (P = 0.155)	3)	



	Events	Total	Weight (common)	Weight (random)	Proportion [95% C	Serious Vascular Toxicit Adverse Drug Reaction
Irug = Afatinib Mountzios,2021	1	59	0.5%	2.7%	0.02 [0.00; 0.09]	† † † † † † † † † † † † † † † † † † †
akata,2023	1	103	1.6%	3.0%	0.01 [0.00; 0.05]	
ū,2022 NCT02131259,2016	8 10	541 1602	5.6% 39.2%	3.2% 3.2%	0.01 [0.01; 0.03] 0.01 [0.00; 0.01]	# +
NCT02047903,2018 2009-014563-39,2013	7 35	152 1154	0.5% 6.0%	2.7% 3.2%	0.05 [0.02; 0.09] 0.03 [0.02; 0.04]	
Smit,2017	1	13	0.0%	0.6%	0.08 [0.00; 0.36]	
NCT02044380,2016 Total (common effect, 95% CI)	5	14 3638	0.0% 53.5%	0.2%	0.36 [0.13; 0.65] 0.01 [0.01; 0.01]	
Total (random effect, 95% CI) Heterogeneity: Tau ² = 0.0001; Chi ²	= 33.46, d			18.8% = 79.1%	0.02 [0.01; 0.03]	•
Irug = Osimertinib						
.orenzi,2022 Kishikawa,2020	15 1	126 56	0.2% 0.5%	2.0% 2.6%	0.12 [0.07; 0.19] 0.02 [0.00; 0.10]	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
Park,2020	4	80	0.3%	2.2%	0.05 [0.01; 0.12]	<u> </u>
NCT02474355,2019 NCT02094261,2015	84 10	3014 210	16.9% 0.7%	3.2% 2.8%	0.03 [0.02; 0.03] 0.05 [0.02; 0.09]	
//alik,2022 //hao,2018	3 2	60 16	0.2% 0.0%	2.0% 0.5%	0.05 [0.01; 0.14] 0.12 [0.02; 0.38]	1 :
(iura,2018	33	301	0.5%	2.6%	0.11 [0.08; 0.15]	+
Provencio,2021 _v,2023	4 1	155 40	0.9% 0.2%	2.9% 2.2%	0.03 [0.01; 0.06] 0.03 [0.00; 0.13]	**
iu,2022	4	32	0.0%	0.9%	0.12 [0.04; 0.29]	
NCT02157883,2015 Zhang,2023	4 1	38 202	0.1% 6.2%	1.1% 3.2%	0.11 [0.03; 0.25] 0.00 [0.00; 0.03]	
subata,2022 2014–000531–17,2024	6 14	33 210	0.0% 0.5%	0.7% 2.7%	0.18 [0.07; 0.35]	
NCT03434418,2022	14	17	0.5%	0.9%		1
Total (common effect, 95% CI) Total (random effect, 95% CI)		4590	27.3%	32.7%	0.03 [0.02; 0.03] 0.05 [0.03; 0.07]	
eterogeneity: Tau ² = 0.0010; Chi ²	= 72.67, c	lf = 15 (P < 0.0001); I		0.00 [0.00, 0.01]	
Irug = Erolotinib NCT01573702,2019	1	25	0.1%	1.5%	0.04 [0.00; 0.20]	1
Irug = Gefitinib		_	_	-		1
Douillard,2014 Schuette,2018	9 6	107 222	0.2% 1.3%	2.1% 3.0%	•	
Cappuzzo,2016	5	58	0.1%	1.6%	0.09 [0.03; 0.19]	
Total (common effect, 95% CI) Total (random effect, 95% CI)		387	1.6%	6.7%	0.04 [0.02; 0.06] 0.06 [0.01; 0.10]	•
Heterogeneity: Tau ² = 0.0009; Chi ²	= 5.68, df	= 2 (P =	= 0.0585); I ² =		, , ,	
Irug = Erlotinib Markóczy,2018	1	62	0.6%	2.7%	0.02 [0.00; 0.09]	
Minemura,2015	1	16	0.0%	0.9%	0.06 [0.00; 0.30]	1
Park,2015 Brueckl,2018	4 2	207 385	1.7% 11.3%	3.0% 3.2%		*
Total (common effect, 95% CI)		670	13.6%	0.00/	0.01 [0.00; 0.01]	★
Total (random effect, 95% CI) Heterogeneity: Tau ² = < 0.0001; Ch	$i^2 = 3.04,$	df = 3 (F	P = 0.3856); I ²	9.8% ² = 1.3%	0.01 [0.00; 0.02]	▼ 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Irug = Befotertinib .u,2022 (50mg)	0.5					
_U,ZUZZ (3UIIIQ)	٠, ١, ١	176	0.20/	2 10/	0.44[0.00+0.20]	
u,2022 (75–100mg) Total (common effect, 95% CI) Total (random effect, 95% CI)	25 38 1, df = 1 (F	176 290 466 P = 0.73	0.2% 0.4% 0.6% 82); I ² = 0%	2.1% 2.5% 4.6%	0.14 [0.09; 0.20] 0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17]	→ ◆ ◆
Lu,2022 (75–100mg) Total (common effect, 95% Cl) Total (random effect, 95% Cl) Heterogeneity: Tau ² = 0; Chi ² = 0.17 Hrug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg)	38 1, df = 1 (F 1 4	290 466 P = 0.73 17 38	0.4% 0.6% 82); $I^2 = 0\%$ 0.0% 0.1%	2.5% • 4.6% 0.9% 1.1%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25]	→ → →
Lu,2022 (75–100mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau ² = 0; Chi ² = 0.1 ² Hrug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (150mg) Tan,2020 (200mg)	38 1, df = 1 (F 1 4 14 1	290 466 P = 0.73 17 38 118 8	0.4% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53]	→ → → →
Lu,2022 (75–100mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg)	38 1, df = 1 (F 1 4 14 1 2	290 466 P = 0.73 17 38 118 8 28	0.4% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.1%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24]	→ → → →
Tu,2022 (75–100mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Hrug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020(300mg) Tan,2020(350mg)	38 1, df = 1 (F 1 4 14 1 2 2 3	290 466 P = 0.73 17 38 118 8 28 5 11	0.4% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.1% 0.0% 0.0%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61]	→ → → →
Total (common effect, 95% CI) Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (300mg) Tan,2020(350mg) Total (common effect, 95% CI) Total (random effect, 95% CI)	38 1, df = 1 (F 1 4 14 1 2 2 3	290 466 P = 0.73 17 38 118 8 28 5 11 225	0.4% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.1% 0.0% 0.0%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85]	→ → → → → → →
Total (common effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Trug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020(300mg) Tan,2020(350mg) Total (common effect, 95% CI)	38 1, df = 1 (F 1 4 14 1 2 2 3	290 466 P = 0.73 17 38 118 8 28 5 11 225	0.4% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.1% 0.0% 0.0%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15]	→ → → → → → →
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (300mg) Tan,2020(350mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch	38 1, df = 1 (F 1 4 14 1 2 2 3	290 466 P = 0.73 17 38 118 8 28 5 11 225	0.4% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.1% 0.0% 0.0%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (300mg) Tan,2020(350mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Furmonertinib Shi,2021 Irug = Almonertinib Yang,2020 (55mg)	38 1, df = 1 (F 1 4 14 1 2 3 $i^2 = 4.74$, 6	290 466 P = 0.73 17 38 118 8 28 5 11 225 df = 6 (F	0.4% 0.6% 0.0% 0.1% 0.2% 0.0% 0.1% 0.0% 0.4% 0.0% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.03 [0.01; 0.06]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (150mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (350mg) Tan,2020(350mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Furmonertinib Shi,2021 Irug = Almonertinib Yang,2020 (55mg) Yang,2020 (110mg)	38 1, df = 1 (F 1 4 14 1 2 3 $i^2 = 4.74$, 6 3 21	290 466 P = 0.73 17 38 118 8 28 5 11 225 df = 6 (F 220	0.4% 0.6% 82); I ² = 0% 0.0% 0.1% 0.0% 0.1% 0.0% 0.4% 2 = 0.5781); I ² 1.3% 0.1% 0.5%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.03 [0.01; 0.06] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (350mg) Tan,2020(350mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Furmonertinib Shi,2021 Irug = Almonertinib Yang,2020 (55mg) Yang,2020 (10mg) Yang,2020 (220mg) Yang,2020 (220mg) Yang,2020 (260mg)	38 1, df = 1 (F 1 4 14 1 2 3 $i^2 = 4.74$, 6	290 466 P = 0.73 17 38 118 28 5 11 225 df = 6 (F 220 36 250 8 6	0.4% 0.6% 0.6% 0.0% 0.1% 0.2% 0.0% 0.1% 0.0% 0.4% 0.0% 0.4% 0.5% 0.0% 0.1% 0.0% 0.0%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (150mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (350mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Furmonertinib Shi,2021 Irug = Almonertinib Yang,2020 (55mg) Yang,2020 (200mg) Yang,2020 (200mg) Yang,2020 (200mg) Yang,2020 (200mg) Yang,2020 (260mg) Total (common effect, 95% CI)	38 1, df = 1 (F 1 4 14 1 2 3 $i^2 = 4.74$, 6 3 21 3	290 466 P = 0.73 17 38 118 8 28 5 11 225 df = 6 (F 220 36 250 8	0.4% 0.6% 0.6% 0.0% 0.1% 0.2% 0.0% 0.1% 0.0% 0.4% 0.0% 0.4% 0.3% 0.4% 0.5% 0.0% 0.5% 0.0%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 0.1² Trug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (350mg) Tan,2020(350mg) Total (common effect, 95% CI) Teterogeneity: Tau² = < 0.0001; Ch Trug = Furmonertinib Trug = Almonertinib Trug = Alm	38 1, df = 1 (F 1 4 14 1 2 3 $i^2 = 4.74$, 6 3 21 3 3	290 466 P = 0.73 17 38 118 28 5 11 225 df = 6 (F 220 36 250 8 6 300	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.0% 0.1% 0.0% 0.4% 0.4% 0.4% 0.5% 0.0% 0.5% 0.0% 0.6%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 1.2% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020(350mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Furmonertinib Shi,2021 Irug = Almonertinib Sang,2020 (220mg) Yang,2020 (110mg) Yang,2020 (220mg) Yang,2020 (260mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0; Chi² = 6.94 Irug = Lazertinib	38 1, df = 1 (F 1 4 14 1 2 3 $i^2 = 4.74$, 6 3 21 3 3	290 466 P = 0.73 17 38 118 28 5 11 225 df = 6 (F 220 36 250 8 6 300	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.0% 0.1% 0.0% 0.4% 0.4% 0.4% 0.5% 0.0% 0.5% 0.0% 0.6%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 1.2% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (350mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Furmonertinib Shi,2021 Irug = Almonertinib Shi,2021 Irug = Almonertinib Sang,2020 (25mg) Yang,2020 (110mg) Yang,2020 (260mg) Total (common effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 6.94 Irug = Lazertinib Cho,2022 (40mg) Cho,2022 (120mg)	38 1, df = 1 (F 1 4 14 1 2 2 3 $i^2 = 4.74$, 6 3 21 3 3 4, df = 3 (F	290 466 P = 0.73 17 38 118 8 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07	0.4% 0.6% 0.6% 0.0% 0.1% 0.2% 0.0% 0.1% 0.0% 0.4% 0.4% 0.4% 0.4% 0.4% 0.5% 0.0% 0.6% 0.0% 0.6% 0.0% 0.1% 0.1%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 4.1% %	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.19] 0.08 [0.01; 0.26]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau ² = 0; Chi ² = 0.17 Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (300mg) Tan,2020 (350mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau ² = < 0.0001; Ch Irug = Almonertinib Tang,2020 (55mg) Tang,2020 (110mg) Tang,2020 (220mg) Tang,2020 (260mg) Total (common effect, 95% CI) Total (random effect, 95% CI)	38 1, df = 1 (F 1 4 14 1 2 2 3 $i^2 = 4.74$, 6 3 21 3 3 4, df = 3 (F	290 466 P = 0.73 17 38 118 8 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07	0.4% 0.6% 0.6% 0.0% 0.1% 0.2% 0.0% 0.1% 0.0% 0.4% 0.4% 0.4% 0.5% 0.0% 0.6% 0.0% 0.6% 0.0% 0.1%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 4.1% 4.1%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.19]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (150mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020(350mg) Tan,2020(350mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Furmonertinib Tang,2020 (25mg) Tang,2020 (55mg) Tang,2020 (55mg) Tang,2020 (200mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Almonertinib Tang,2020 (20mg) Total (common effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 6.94 Irug = Lazertinib Tang = Lazertinib Tang,2022 (120mg) Total (2022 (120mg) Total (2022 (120mg) Total (2022 (240mg) Total (240mg) Tang,2021 (240mg) Tang,2022 (240mg) Tang,2022 (240mg) Tang = Lazertinib Tang = Tang	38 1, df = 1 (F 1 4 14 1 2 2 3 $i^2 = 4.74$, 6 6 3 21 3 3 4, df = 3 (F 1 2 1 10 4	290 466 P = 0.73 17 38 118 8 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102 15	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.0% 0.0% 0.4% 0.4% 0.5% 0.0% 0.6% 0.0% 0.6% 0.1% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 3.0% 1.2% 2.6% 0.1% 0.1% 4.1% % 1.6% 1.0% 1.4% 2.0% 0.3%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.26] 0.04 [0.00; 0.22] 0.10 [0.05; 0.17] 0.27 [0.08; 0.55]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (150mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020(350mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Almonertinib Tang,2020 (55mg) Tang,2020 (100mg) Total (random effect, 95% CI) Total (common effect, 95% CI) Total (random Total (240mg)	38 1, df = 1 (F 1 4 14 1 2 2 3 i ² = 4.74, 6 6 3 21 3 3 4, df = 3 (F 1 2 1 10 4 3	290 466 P = 0.73 17 38 118 8 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.4% 0.4% 0.4% 0.5% 0.0% 0.5% 0.0% 0.6% 0.6% 0.6% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 4.1% % 1.6% 1.0% 1.4% 2.0% 0.3% 0.3% 0.3% 0.3%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.03 [0.01; 0.06] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.26] 0.04 [0.00; 0.26] 0.04 [0.00; 0.22] 0.10 [0.05; 0.17] 0.27 [0.08; 0.55] 0.23 [0.05; 0.54] 0.08 [0.04; 0.11]	→ <p< td=""></p<>
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (150mg) Tan,2020 (225mg) Tan,2020 (225mg) Tan,2020(350mg) Tan,2020(350mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Almonertinib Tang,2020 (25mg) Tang,2020 (55mg) Tang,2020 (55mg) Tang,2020 (55mg) Tang,2020 (20mg) Tang,2020 (20mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Total (common effect, 95% CI) Total (common effect, 95% CI) Total (random effect, 95% CI)	38 1, df = 1 (F 1, 4 14 1, 2 3 $i^2 = 4.74$, 6 3 3, 3 4, df = 3 (F 1, 2 1, 10 4, 3	290 466 P = 0.73 17 38 118 8 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102 15 13 205	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.4% 0.4% 0.4% 0.5% 0.0% 0.6% 0.0% 0.6% 0.1% 0.1% 0.2% 0.0% 0.4% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 4.1% 4.1% 6.6% 6.6%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.22] 0.10 [0.05; 0.17] 0.27 [0.08; 0.55] 0.23 [0.05; 0.54]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (300mg) Tan,2020 (350mg) Tan,2020(350mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Furmonertinib Tang,2020 (55mg) Tang,2020 (110mg) Tang,2020 (220mg) Tang,2020 (220mg) Tang,2020 (260mg) Total (common effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 6.94 Irug = Lazertinib Total (random effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Total (common effect, 95% CI) Total (random effect, 95% CI)	38 1, df = 1 (F 1 4 14 1 2 2 3 $i^2 = 4.74$, 6 4 3 4, df = 3 (F 1 2 1 10 4 3 $i^2 = 6.83$, 6	290 466 P = 0.73 17 38 118 8 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102 15 13 205 df = 5 (F	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.4% 0.0% 0.4% 0.5% 0.0% 0.0% 0.6% 0.6% 0.1% 0.1% 0.1% 0.2% 0.0% 0.4% 0.1% 0.1% 0.1% 0.1% 0.2% 0.0% 0.4% 0.2% 0.0% 0.4% 0.2% 0.0% 0.4% 0.2% 0.0% 0.4% 0.2% 0.0% 0.4% 0.2% 0.0% 0.4% 0.2% 0.0% 0.4% 0.2% 0.0% 0.4%	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 0.1% 0.1% 6.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.26] 0.04 [0.00; 0.22] 0.10 [0.05; 0.17] 0.27 [0.08; 0.55] 0.23 [0.05; 0.54] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11]	* * * * * * * * * * * * *
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (300mg) Tan,2020 (350mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Almonertinib Tang,2020 (55mg) Tang,2020 (55mg) Tang,2020 (200mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Almonertinib Tang,2020 (200mg) Total (common effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 6.94 Irug = Lazertinib Cho,2022 (40mg) Cho,2022 (120mg) Cho,2022 (120mg) Cho,2022 (120mg) Cho,2022 (120mg) Cho,2022 (240mg) Cho,2022 (240mg) Cho,2022 (240mg) Cho,2022 (240mg) Cho,2022 (240mg) Total (common effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Mobocertinib Hida,2021 (120mg) Hida,2021 (120mg) Hida,2021 (160mg)	38 1, df = 1 (F 1, 4 14 1, 2 3 $i^2 = 4.74$, 6 3 3, 3 4, df = 3 (F 1, 2 1, 10 4, 3	290 466 P = 0.73 17 38 118 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102 15 13 205 df = 5 (F 45	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.4% 0.4% 0.4% 0.5% 0.0% 0.6% 0.0% 0.6% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 4.1% 4.1% 6.6% 6.6%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.26] 0.04 [0.00; 0.26] 0.04 [0.00; 0.22] 0.10 [0.05; 0.17] 0.27 [0.08; 0.55] 0.23 [0.05; 0.54] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (350mg) Tan,2020(350mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Furmonertinib Tang,2020 (55mg) Tang,2020 (55mg) Tang,2020 (110mg) Tang,2020 (220mg) Tang,2020 (20mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 6.9² Irug = Lazertinib Cho,2022 (40mg) Cho,2022 (120mg) Cho,2022 (120mg) Cho,2022 (120mg) Cho,2022 (120mg) Cho,2022 (240mg) Cho,2022 (240mg) Cho,2022 (120mg) Cho,2022 (240mg) Cho,2022 (240mg) Total (common effect, 95% CI) Total (random effect, 95% CI)	38 1, df = 1 (F 1 4 14 1 2 2 3 $i^2 = 4.74$, $i^2 = 4.74$, $i^3 = 6.83$, $i^3 = 6.$	290 466 P = 0.73 17 38 118 8 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102 13 205 df = 5 (F 4 45 49	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.4% 0.0% 0.4% 0.5% 0.0% 0.6% 0.0% 0.6% 0.1% 0.1% 0.1% 0.2% 0.0% 0.4% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 4.1% 4.1% 6.6% 1.0% 1.4% 2.0% 0.3% 0.3% 0.3% 1.2% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.0% 1.0%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.29] 0.05; 0.17] 0.07 [0.08; 0.55] 0.23 [0.05; 0.54] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11]	* * * * * * * * * * * * *
Total (common effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 0.1² Trug = Nazartinib Tan, 2020 (75mg) Tan, 2020 (100mg) Tan, 2020 (200mg) Tan, 2020 (225mg) Tan, 2020 (300mg) Tan, 2020 (350mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau² = < 0.0001; Ch Trug = Almonertinib Tang, 2020 (55mg) Tang, 2020 (220mg) Tang, 2020 (220mg) Tang, 2020 (260mg) Total (common effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 6.94 Trug = Lazertinib Tho, 2022 (40mg) Tho, 2022 (120mg) Tho, 2022 (240mg) Total (common effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 6.94 Trug = Lazertinib Tho, 2022 (120mg) Tho, 2022 (120mg) Tho, 2022 (120mg) Tho, 2022 (120mg) Total (common effect, 95% CI) Teterogeneity: Tau² = < 0.0001; Ch Total (random effect, 95% CI) Teterogeneity: Tau² = < 0.0001; Ch Total (random effect, 95% CI)	38 1, df = 1 (F 1 4 14 1 2 2 3 $i^2 = 4.74$, $i^2 = 4.74$, $i^3 = 6.83$, $i^3 = 6.$	290 466 P = 0.73 17 38 118 8 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102 13 205 df = 5 (F 4 45 49	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.4% 0.0% 0.4% 0.5% 0.0% 0.6% 0.0% 0.6% 0.1% 0.1% 0.1% 0.2% 0.0% 0.4% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 4.1% 4.1% 6.6% 1.0% 1.4% 2.0% 0.3% 0.3% 0.3% 1.2% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.0% 1.0%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.22] 0.10 [0.05; 0.17] 0.27 [0.08; 0.55] 0.23 [0.05; 0.54] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11] 0.09 [0.11; 0.32]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 0.1² Irug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (350mg) Tan,2020(350mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = < 0.0001; Ch Irug = Furmonertinib Tang,2020 (55mg) Tang,2020 (55mg) Tang,2020 (110mg) Tang,2020 (220mg) Tang,2020 (20mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Heterogeneity: Tau² = 0; Chi² = 6.9² Irug = Lazertinib Cho,2022 (40mg) Cho,2022 (120mg) Cho,2022 (120mg) Cho,2022 (120mg) Cho,2022 (120mg) Cho,2022 (240mg) Cho,2022 (240mg) Cho,2022 (120mg) Cho,2022 (240mg) Cho,2022 (240mg) Total (common effect, 95% CI) Total (random effect, 95% CI)	38 1, df = 1 (F 1 4 14 1 2 2 3 $i^2 = 4.74$, $i^2 = 4.74$, $i^3 = 6.83$, $i^3 = 6.$	290 466 P = 0.73 17 38 118 8 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102 13 205 df = 5 (F 4 45 49	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.4% 0.0% 0.4% 0.5% 0.0% 0.6% 0.0% 0.6% 0.1% 0.1% 0.1% 0.2% 0.0% 0.4% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 4.1% 4.1% 6.6% 1.0% 1.4% 2.0% 0.3% 0.3% 0.3% 1.2% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.4% 2.0% 1.0% 1.0% 1.0%	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.22] 0.10 [0.05; 0.17] 0.27 [0.08; 0.55] 0.23 [0.05; 0.54] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11] 0.09 [0.11; 0.32]	
Total (common effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 0.1² Tan, 2020 (75mg) Tan, 2020 (100mg) Tan, 2020 (200mg) Tan, 2020 (225mg) Tan, 2020 (350mg) Total (common effect, 95% CI) Teterogeneity: Tau² = < 0.0001; Ch Total (random effect, 95% CI) Total (random effect, 95% CI) Total (common effect, 95% CI) Total (common effect, 95% CI) Total (common effect, 95% CI) Total (random effect, 95% CI)	38 1, df = 1 (F 1	290 466 P = 0.73 17 38 118 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102 15 13 205 df = 5 (F 45 49 = 1 (P = 25)	0.4% 0.6% 0.6% 0.0% 0.1% 0.2% 0.0% 0.1% 0.0% 0.4% 0.4% 0.5% 0.0% 0.6% 0.6% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 1.0% 1.4% 2.0% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.03 [0.01; 0.06] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.29] 0.08 [0.01; 0.26] 0.04 [0.00; 0.29] 0.10 [0.05; 0.17] 0.27 [0.08; 0.55] 0.23 [0.05; 0.54] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11] 0.75 [0.19; 0.99] 0.18 [0.08; 0.32] 0.21 [0.11; 0.32] 0.43 [0.00; 0.98]	* * * * * * * * * * * * *
Total (common effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 0.1² Trug = Nazartinib Tan,2020 (75mg) Tan,2020 (100mg) Tan,2020 (200mg) Tan,2020 (225mg) Tan,2020 (300mg) Tan,2020 (350mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau² = < 0.0001; Ch Trug = Almonertinib Trang,2020 (55mg) Trang,2020 (110mg) Trang,2020 (220mg) Trang,2020 (220mg) Trang,2020 (260mg) Total (common effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 6.9² Trug = Lazertinib Trang,2022 (120mg) Trang,2022 (1	38 1, df = 1 (F 1, 4 14 1, 2 2, 3 $i^2 = 4.74$, 6 3, 21 3, 3 4, df = 3 (F 1, 2 1, 10 4, 3 $i^2 = 6.83$, 6 3, 8 = 6.53, df	290 466 P = 0.73 17 38 118 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102 15 13 205 df = 5 (F 45 49 = 1 (P =	0.4% 0.6% 0.6% 0.0% 0.1% 0.2% 0.0% 0.1% 0.0% 0.4% 0.4% 0.5% 0.0% 0.6% 0.6% 0.1% 0.1% 0.1% 0.2% 0.0% 0.6% 0.0% 0.4% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 1.4% 2.0% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.03 [0.01; 0.06] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.29] 0.10 [0.05; 0.17] 0.27 [0.08; 0.55] 0.23 [0.05; 0.54] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11] 0.075 [0.19; 0.99] 0.18 [0.08; 0.32] 0.21 [0.11; 0.32] 0.43 [0.00; 0.98]	* * * * * * * * * * * * *
Total (common effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 0.1² Trug = Nazartinib Tan,2020 (75mg) Tan,2020 (150mg) Tan,2020 (225mg) Tan,2020 (225mg) Tan,2020 (350mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau² = < 0.0001; Ch Trug = Almonertinib Trug,2020 (25mg) Trug,2020 (55mg) Trug,2020 (55mg) Trug,2020 (110mg) Trug,2020 (25mg) Trug,2020 (20mg) Total (common effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 6.9² Trug = Lazertinib Tho,2022 (40mg) Tho,2022 (40mg) Tho,2022 (120mg) Tho,2022 (120mg) Tho,2022 (120mg) Tho,2022 (120mg) Total (common effect, 95% CI) Teterogeneity: Tau² = < 0.0001; Ch Total (random effect, 95% CI) Teterogeneity: Tau² = < 0.0001; Ch Total (random effect, 95% CI) Teterogeneity: Tau² = 0.1387; Chi² Trug = Dacomitinib Total (random effect, 95% CI) Teterogeneity: Tau² = 0.1387; Chi² Trug = Dacomitinib Total (common effect, 95% CI) Total (random effect, 95% CI) Total (common effect, 95% CI) Total (common effect, 95% CI) Total (common effect, 95% CI)	38 1, df = 1 (F 1	290 466 P = 0.73 17 38 118 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102 15 13 205 df = 5 (F 45 49 = 1 (P = 25) 48	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.4% 0.4% 0.5% 0.0% 0.6% 0.0% 0.6% 0.1% 0.1% 0.1% 0.2% 0.0% 0.6% 0.0% 0.4% 0.1% 0.1% 0.2% 0.0% 0.4% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 0.1% 0.1% 1.6% 1.0% 1.4% 2.0% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.03 [0.01; 0.06] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.26] 0.04 [0.00; 0.22] 0.10 [0.05; 0.17] 0.27 [0.08; 0.55] 0.23 [0.05; 0.54] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11] 0.08 [0.00; 0.98] 0.12 [0.03; 0.31]	* * * * * * * * * * * * * * * * * * *
Total (common effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 0.1² Tan, 2020 (75mg) Tan, 2020 (100mg) Tan, 2020 (200mg) Tan, 2020 (225mg) Tan, 2020 (350mg) Total (common effect, 95% CI) Teterogeneity: Tau² = < 0.0001; Ch Total (random effect, 95% CI) Teterogeneity: Tau² = < 0.0001; Ch Total (common effect, 95% CI) Total (common effect, 95% CI) Total (common effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 6.9² Total (random effect, 95% CI)	38 1, df = 1 (F 1, df = 1 (F 1, df = 1) 1, df = 1 (F 1, df = 3) 3 4, df = 3 (F 1, df = 3) 3 4, df = 3 (F 1, df = 3) 3 4, df = 3 (F 1, df = 3) 3 4, df = 3 (F 1, df = 3) 4, df = 3 (F 1, df = 3) 1, df = 3 (F 1, df = 3) 3 4, df = 3 (F 1, df = 3) 4, df = 3 (F 1, df = 3) 1, df = 3 (F 1, df = 3) 3 4, df = 3 (F 1, df = 3) 4, df =	290 466 P = 0.73 17 38 118 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102 15 13 205 df = 5 (F 45 49 49 101 101 101 101 101 101 101 10	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.4% 0.4% 0.5% 0.0% 0.6% 0.6% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 0.1% 4.1% 6.6% 2 = 26.8% 0.1% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.11] 0.08 [0.01; 0.26] 0.04 [0.00; 0.22] 0.10 [0.05; 0.17] 0.27 [0.08; 0.55] 0.23 [0.05; 0.54] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11] 0.075 [0.19; 0.99] 0.18 [0.08; 0.32] 0.21 [0.11; 0.32] 0.43 [0.00; 0.98]	* * * * * * * * * * * * * * * * * * *
Total (common effect, 95% CI) Total (random effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 0.1 Trug = Nazartinib Tan,2020 (75mg) Tan,2020 (150mg) Tan,2020 (225mg) Tan,2020 (225mg) Tan,2020 (350mg) Tan,2020 (350mg) Total (common effect, 95% CI) Total (random effect, 95% CI) Teterogeneity: Tau² = < 0.0001; Ch Trug = Furmonertinib Tang,2020 (55mg) Tang,2020 (55mg) Tang,2020 (110mg) Tang,2020 (220mg) Tang,2020 (20mg) Total (common effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 6.94 Trug = Lazertinib Tang,2020 (240mg) Total (random effect, 95% CI) Teterogeneity: Tau² = 0; Chi² = 6.94 Trug = Lazertinib Tang,2022 (120mg) Tang,2023 (120mg) Tang,2021 (120mg) Tang,2020 (120mg) Tang,2	38 1, df = 1 (F 1	290 466 P = 0.73 17 38 118 28 5 11 225 df = 6 (F 220 36 250 8 6 300 P = 0.07 27 25 23 102 15 13 205 df = 5 (F 45 49 49 101 101 101 101 101 101 101 10	0.4% 0.6% 0.6% 82); I ² = 0% 0.0% 0.1% 0.2% 0.0% 0.4% 0.4% 0.5% 0.0% 0.6% 0.6% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1	2.5% 4.6% 0.9% 1.1% 1.9% 0.3% 1.2% 0.1% 0.2% 5.8% 2 = 0% 3.0% 1.2% 2.6% 0.1% 0.1% 0.1% 0.1% 0.1% 1.6% 1.0% 1.4% 2.0% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0	0.13 [0.09; 0.18] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.14 [0.10; 0.17] 0.06 [0.00; 0.29] 0.11 [0.03; 0.25] 0.12 [0.07; 0.19] 0.12 [0.00; 0.53] 0.07 [0.01; 0.24] 0.40 [0.05; 0.85] 0.27 [0.06; 0.61] 0.11 [0.07; 0.15] 0.11 [0.07; 0.15] 0.03 [0.01; 0.06] 0.08 [0.02; 0.22] 0.08 [0.05; 0.13] 0.38 [0.09; 0.76] 0.50 [0.12; 0.88] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.09 [0.06; 0.12] 0.04 [0.00; 0.26] 0.04 [0.00; 0.22] 0.10 [0.05; 0.17] 0.27 [0.08; 0.55] 0.23 [0.05; 0.54] 0.08 [0.04; 0.11] 0.08 [0.04; 0.11] 0.08 [0.00; 0.98] 0.12 [0.03; 0.31]	

